Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients
Savino Sciascia(Ospedale San Giovanni Bosco), Dario Roccatello(5T Torino (Italy)), Giulio Mengozzi, Simone Baldovino(Azienda Ospedaliero Universitaria San Giovanni Battista), María Laura Bertolaccini(St Thomas' Hospital), A Vaccarino(Istituto di Ematologia di Bologna), Elena Rubini(Ospedale San Giovanni Bosco), Daniela Rossi(University of Siena), Massimo Radin(Ospedale San Giovanni Bosco), Osvaldo Giachino, Maria Tiziana Bertero(University of Turin), Mario Bazzan(Ospedale San Giovanni Bosco), Irene Cecchi(Ospedale San Giovanni Bosco)
Cited by 37
Related Papers
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
|New England Journal of Medicine|2001|599
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404
GAPSS: the Global Anti-Phospholipid Syndrome Score
|Lara D. Veeken|2013|310
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
|Journal of Clinical Oncology|2005|305
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
|Arthritis & Rheumatology|2021|165